Table 3 Cox regression analysis for LUAD patients harboring KRAS mutations
From: Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients
Covariates | A. K-Ras4A expression | Covariates | B. K-Ras4A proportion | ||||||
|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
HRa (95% CIb) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
Age (≥65 years) | 1.326 (0.761−2.312) | 0.320 | 1.351 (0.735−2.480) | 0.333 | Age (≥65 years) | 1.326 (0.761−2.312) | 0.320 | 1.443 (0.778−2.678) | 0.245 |
Gender (Male) | 1.536 (0.891−2.650) | 0.123 | 1.734 (0.954−3.152) | 0.0711 | Gender (Male) | 1.536 (0.891−2.650) | 0.123 | 1.690 (0.911−3.061) | 0.0971 |
Smoking history | 1.076 (0.804−1.440) | 0.622 | 1.168 (0.851−1.602) | 0.337 | Smoking history | 1.076 (0.804−1.440) | 0.622 | 1.191 (0.866−1.638) | 0.282 |
KRAS amplification (Not amplified) | 0.820 (0.410−1.643) | 0.576 | 0.802 (0.383−1.679) | 0.558 | KRAS amplification (Not amplified) | 0.820 (0.410−1.643) | 0.576 | 0.954 (0.448−2.031) | 0.903 |
K-Ras4A expression (low) | 1.986 (1.131−3.490) | 0.017 | 2.533 (1.380−4.651) | 2.72E-3 | K-Ras4A proportion (low) | 2.258 (1.295−3.938) | 4.10E-3 | 2.549 (1.387−4.684) | 2.58E-3 |
Pathological stage (III/IV) | 3.088 (1.747−5.459) | 1.05E-4 | 3.268 (1.793−5.954) | 1.10E-4 | Pathological stage (III/IV) | 3.088 (1.747−5.459) | 1.05E-4 | 3.404 (1.867−6.207) | 6.41E-5 |